Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Hepatitis B Foundation reveals alternative to liver biopsy for monitoring liver disease

Hepatitis B Foundation : 20 December, 2007  (New Product)
Researchers working at the Hepatitis B Foundation and the Drexel University College of Medicine believe they have discovered a reliable alternative to liver biopsy for the early detection of liver fibrosis and cirrhosis.
Liver fibrosis and cirrhosis afflict more than five million Americans. People with hepatitis B and C infections, as well as fatty liver diseases, are at greatest risk for progressing to cirrhosis that can lead to liver cancer.

Successful treatment depends on the early detection of fibrosis and cirrhosis. Currently, detection involves a surgical liver biopsy, which is an unpleasant, expensive procedure and carries some risk. Patients and doctors would prefer tests that are ‘not invasive’ such as a blood test to detect and monitor liver disease.

Lead investigators Drs Anand Mehta and Timothy Block report in the upcoming Journal of Virology, which appears online next week and in print February 2008, their discovery that the blood of most, if not all, people they tested with a diagnosis of liver cirrhosis, contains high levels of a special antibody that recognises a carbohydrate sugar commonly found on bacteria. Detection of this antibody in the blood of an affected person correlates well with a diagnosis of increasing fibrosis and cirrhosis in the new study.

'This is a fascinating discovery and is important because, if confirmed, the test could help us replace liver biopsy as a method for staging liver disease. In addition, it may be teaching us something about how liver disease occurs,' said David Thomas, MD, chief, Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Working with the National Cancer Institute (NCI) Early Detection Research Network, the researchers have been able to test this approach in 300 blood samples from people with liver disease, and can conduct the new test in thousands. Although the test is still experimental and more is needed before it can be used to monitor disease, the discovery is promising.

'If this work is validated, it may offer a new, non-invasive way to test for liver disease, allowing people to either avoid biopsy or to know when they really need one. It also implies that bacteria may have a much bigger role in initiating liver disease than realized, and even lead to new therapies,' said Block.

Complications from bacteria in people with cirrhosis are well understood; however, bacteria are not usually seen early in the disease. The significance of this new discovery may suggest earlier treatments with antibiotics could benefit patients with chronic liver disease.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo